Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jacc.2025.07.035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineering the Future of Stem Cells in Vascular Reconstruction: A Leap Towards Functional Endothelialized Tissue-Engineered Vascular Conduits.
Stem Cell Rev Rep
September 2025
Paris Cité University, INSERM UMR-S 970, Paris Cardiovascular Research Centre, Paris, France.
The transition from reconstructive to regenerative strategies in vascular surgery has intensified the need for grafts that are biocompatible, growth-capable, and resistant to thrombosis. Addressing this challenge, Park et al. introduce a groundbreaking method for engineering fully biological, endothelialized tissue-engineered vascular conduits (TEVCs) using decellularized human umbilical arteries (dHUAs) coated with human induced pluripotent stem cell-derived endothelial cells (hiPSC-ECs).
View Article and Find Full Text PDFControversies in Antithrombotic Therapy for Patients With Coronary Artery Disease and Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Literature Review.
Clin Med Insights Cardiol
August 2025
Department of Internal Medicine, Advocate Illinois Masonic Medical Center, Chicago, IL, USA.
CAD and AF are 2 of the major cardiovascular challenges worldwide, often coexisting and complicating management strategies. PCI has revolutionized the treatment of CAD, reducing mortality and improving recovery. At the same time, AF increases the risk of stroke, thus requiring anticoagulation.
View Article and Find Full Text PDFAspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation.
N Engl J Med
August 2025
ACTION Group, Paris.
Background: The appropriate antithrombotic regimen for patients with chronic coronary syndrome who are at high atherothrombotic risk and receiving long-term oral anticoagulation remains unknown.
Methods: We conducted a multicenter, double-blind, randomized, placebo-controlled trial in France involving patients with chronic coronary syndrome who had undergone a previous stent implantation (>6 months before enrollment) and were at high atherothrombotic risk and currently receiving long-term oral anticoagulation. The patients were randomly assigned in a 1:1 ratio to receive aspirin (100 mg once daily) or placebo; all the patients continued to receive their current oral anticoagulation therapy.
Real World Applicability Of Voyager-Pad According To Oac3pad Score.
Port J Card Thorac Vasc Surg
August 2025
Angiology and Vascular Surgery Department, Vila Nova de Gaia/Espinho Hospital, Portugal.
Introduction: Lower extremity peripheral artery disease (PAD) is associated with a high risk of cardiovascular and limb adverse events. Optimal post intervention antithrombotic strategy may significantly impact medium to long-term outcomes. The VOYAGER PAD trial showed a clinical benefit of combining low dose rivaroxaban plus aspirin by reducing cardiovascular and limb major adverse events.
View Article and Find Full Text PDFPrevention and treatment of venous thromboembolism in patients with multiple myeloma: Clinical practice guidelines on behalf of the European Myeloma Network.
Hemasphere
August 2025
Department of Clinical Therapeutics Plasma Cell Dyscrasias Unit, National and Kapodistrian University of Athens, School of Medicine Athens Greece.
Venous thromboembolism (VTE) is a frequent complication in patients with multiple myeloma (MM) that leads to increased morbidity, mortality, treatment interruptions, and reduced quality of life. Αn Expert Panel Consensus Guideline on behalf of the European Myeloma Network provides evidence-based recommendations for VTE prevention and treatment in patients with MM. Key recommendations include the following: .
View Article and Find Full Text PDF